Aymen Kabir

Aymen Kabir

Auto-generated profile, based on publicly available information

Aymen Kabir

University of California, San Francisco

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Science Advances
Verified
Journal Article
Open access
MMMulki Mehari
Mulki Mehari
GWGayathri Warrier
Gayathri Warrier
ADAbraham Dada
Abraham Dada
AKAymen Kabir
Aymen Kabir
AHAden P. Haskell-Mendoza
Aden P. Haskell-Mendoza
SHShawn Hervey-Jumper
Shawn Hervey-Jumper
Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factors remains limited. To test the interactive effects of demographic, socioeconomic, and oncologic variables on trial enrollment, we designed boosted neural networks (BNNs) for all glioma patients ( n = 1042), women ( n = 445, 42.7%), and minorities ( n = 151, 14.5%) and externally validated these models [whole cohort, n = 230; women, n = 89 (38.7%); minority, n = 66 (28.7%)]. For the whole-cohort BNN, the most influential variables on enrollment were oncologic variables, including KPS [total effect (TE), 0.327], chemotherapy (TE, 0.326), tumor location (TE, 0.322), and seizures (TE, 0.239). The women-only BNN exhibited a similar trend. Conversely, for the minority-only BNN, socioeconomic variables [insurance status (TE, 0.213), occupation classification (TE, 0.204), and employment status (TE, 0.150)] were most influential. These results may help prioritize patient-specific initiatives to increase accrual.

17 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AKAymen Salahadin Kabir
Aymen Salahadin Kabir
ADAbraham Dada
Abraham Dada
WSWesley Shoap
Wesley Shoap
RRRithvik Ramesh
Rithvik Ramesh
DQDaniel Quintana
Daniel Quintana
EGEzequiel Goldschmidt
Ezequiel Goldschmidt
Background: Meningioma–induced hyperostosis (MIH) is a frequent radiographic finding, yet its underlying mechanisms remain poorly understoodWhile hyperostosis has traditionally been treated as a binary phenomenon, the aim of this study was to determine whether MIH represents a heterogenous process with distinct radiological subtypes associated with genetic associations. Methods: We retrospectively reviewed the records and imaging of patients with meningiomas resected between 2021–2024 at a single institution. Somatic mutations identified through next–generation sequencing were analyzed. CT images were analyzed for bone involvement and hyperostosis subtype. Type I hyperostosis was defined by destruction of cortical architecture while Type II hyperostosis was defined by the preservation of cortical structure. Associations with TRAF7 mutations were assessed using univariate testing, multivariable logistic regression, and supervised machine–learning models. Quantitative bone density analysis was performed using region–of–interest grayscale histogram analysis. Results: Among 384 tumors, 54 (14.1%) exhibited hyperostosis—23 Type I and 31 Type II. TRAF7 mutations were significantly enriched in Type I hyperostosis compared with Type II and non–hyperostotic tumors (78.3% vs 25.8% vs 17.0%, p<0.001). Type I hyperostosis independently predicted TRAF7 mutations (OR:18.73, p=0.001), along with skull base location, smaller tumor size, homogeneous contrast enhancement, and extensive T2 hyperintensity. Gradient boosting achieved the highest predictive accuracy (AUC=0.854). Quantitative bone density analysis demonstrated preserved cortical–cancellous architecture in Type II hyperostosis, whereas Type I showed architectural disruption. Conclusions: MIH is a radiographically heterogenous phenomenon. Hyperostosis with disrupted cortical architecture is strongly associated with TRAF7 mutations and may represent a key feature of this mutation's radiographic phenotype.

22 May 2025 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
AKAymen Kabir
Aymen Kabir
SSSuraj Shah
Suraj Shah
AHAlexander F Haddad
Alexander F Haddad
MAMatthew R Amans
Matthew R Amans
DCDaniel L Cooke
Daniel L Cooke
DRDaniel Raper
Daniel Raper
Introduction External ventricular drain (EVD) placement is a life-saving neurosurgical procedure used to divert cerebrospinal fluid and reduce intracranial pressure in conditions such as subarachnoid hemorrhage, intraparenchymal hemorrhage, and intraventricular hemorrhage. While known complications include infection and hemorrhage, the formation of iatrogenic dural arteriovenous fistulas (dAVFs) following ventriculostomy is under-reported. Methods We conducted a retrospective review of patients at our institution from 2002 to 2023 who developed dAVFs after EVD placement. Inclusion criteria required angiographic confirmation of a new dAVF near the EVD site. Demographics, primary pathology, EVD characteristics, angiographic findings, treatment approach, and outcomes were recorded. Results Sixteen patients met the inclusion criteria. Subarachnoid hemorrhage was the most common indication for EVD placement (75.0%). All drains were placed at Kocher’s point, most commonly on the right (75.0%). All dAVFs involved the middle meningeal artery, with venous drainage documented in 93.8%—most frequently into the middle meningeal vein (80.0%). Eight patients (50.0%) underwent treatment, primarily with ethanol embolization (62.5%). All treated cases achieved radiographic cure without complications. Two patients experienced spontaneous resolution. Three patients were managed conservatively for low-risk fistulas and five were lost to follow-up. Conclusion This study presents the largest institutional series to date of iatrogenic dAVFs following ventriculostomy. While rare, iatrogenic dAVFs have the potential for significant morbidity if they develop complications from venous hypertension and may require additional treatments. Our findings highlight the need for awareness of identifying and appropriately managing ventriculostomy-related dAVFs.